Aerska has developed an antibody-oligonucleotide conjugate (AOC) platform that uses “brain shuttles” to help deliver RNAi directly to the brain, allowing for better uptake by neurons and lasting gene knockdown.
Aerska has raised €51M across 2 funding rounds from 12 investors, most recently a Series A round in Feb 2026. Based in Dublin, Ireland; active in Healthtech. Data as of 6 Aug 2026.
Timing: too soon vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2026-02-09 | Series A | €33M | Age1,EQT Dementia Fund,Existing investors,Iaso Ventures | View deal → |
| 2025-10-01 | Seed | €18M | Ada Ventures,Age1,Backed VC,BlueYard,Kerna,Lingotto+3 more | View deal → |
